NASDAQ:ADMA - ADMA Biologics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.22 +0.40 (+10.47 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$4.22
Today's Range$3.80 - $4.41
52-Week Range$2.08 - $6.96
Volume1.01 million shs
Average Volume578,308 shs
Market Capitalization$195.60 million
P/E Ratio-2.21
Dividend YieldN/A
Beta2.88
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. In Addition, the company offers Nabi-HB for the treatment of acute exposure; and Bivigam for the treatment of primary humoral immunodeficiency. It distributes its products through independent distributors, sales agents, specialty pharmacies, and others. The ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

Receive ADMA News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMA
CUSIPN/A
Phone201-478-5552

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.76 million
Book Value$0.89 per share

Profitability

Net Income$-43,750,000.00
Net Margins-243.42%

Miscellaneous

Employees295
Market Cap$195.60 million
OptionableOptionable

ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

How were ADMA Biologics' earnings last quarter?

ADMA Biologics Inc (NASDAQ:ADMA) posted its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.33) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.31) by $0.02. The biotechnology company earned $4.23 million during the quarter, compared to analyst estimates of $5.39 million. ADMA Biologics had a negative net margin of 243.42% and a negative return on equity of 155.19%. View ADMA Biologics' Earnings History.

When is ADMA Biologics' next earnings date?

ADMA Biologics is scheduled to release their next quarterly earnings announcement on Monday, March 4th 2019. View Earnings Estimates for ADMA Biologics.

What price target have analysts set for ADMA?

5 analysts have issued 12-month price targets for ADMA Biologics' shares. Their predictions range from $7.50 to $13.00. On average, they anticipate ADMA Biologics' stock price to reach $10.4167 in the next year. This suggests a possible upside of 146.8% from the stock's current price. View Analyst Price Targets for ADMA Biologics.

What is the consensus analysts' recommendation for ADMA Biologics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ADMA Biologics.

What are Wall Street analysts saying about ADMA Biologics stock?

Here are some recent quotes from research analysts about ADMA Biologics stock:
  • 1. HC Wainwright analysts commented, "We value ADMA via discounted cash flow (DCF)-based analysis, which models four principal lines of business (Nabi-HB, plasma reselling from its own plasma center, BIVIGAM and RI-002). We apply a 10% discount rate and 30% effective tax rate, along with a 2.5% terminal growth rate." (2/7/2019)
  • 2. Maxim Group analysts commented, "ADMA announced that FDA has accepted the BLA resubmission for RI-002, the company’s specialized IVIG immunoglobulin for Primary Immune Deficiency Disease (PIDD) and assigned a PDUFA date on April 2, 2019." (10/17/2018)

Has ADMA Biologics been receiving favorable news coverage?

Media stories about ADMA stock have trended somewhat negative this week, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ADMA Biologics earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days.

Who are some of ADMA Biologics' key competitors?

Who are ADMA Biologics' key executives?

ADMA Biologics' management team includes the folowing people:
  • Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 42)
  • Dr. Jerrold B. Grossman D.P.S., Co-Founder & Vice Chairman (Age 71)
  • Mr. Brian Lenz CPA, Exec. VP & CFO (Age 47)
  • Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 73)
  • Mr. James Hauert, Sr. VP of Commercialization & Strategy

Who are ADMA Biologics' major shareholders?

ADMA Biologics' stock is owned by many different of retail and institutional investors. Top institutional investors include Broadfin Capital LLC (9.12%), BlackRock Inc. (2.08%), Geode Capital Management LLC (0.60%), Diag Capital Management LP (0.39%), Delek Group Ltd. (0.26%) and Pura Vida Investments LLC (0.08%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond and Jerrold B Grossman. View Institutional Ownership Trends for ADMA Biologics.

Which major investors are selling ADMA Biologics stock?

ADMA stock was sold by a variety of institutional investors in the last quarter, including Pura Vida Investments LLC and Broadfin Capital LLC. View Insider Buying and Selling for ADMA Biologics.

Which major investors are buying ADMA Biologics stock?

ADMA stock was acquired by a variety of institutional investors in the last quarter, including Diag Capital Management LP, Delek Group Ltd., Geode Capital Management LLC, Dimensional Fund Advisors LP, United Services Automobile Association, Raymond James & Associates, Rhumbline Advisers and BlackRock Inc.. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond and Jerrold B Grossman. View Insider Buying and Selling for ADMA Biologics.

How do I buy shares of ADMA Biologics?

Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ADMA Biologics' stock price today?

One share of ADMA stock can currently be purchased for approximately $4.22.

How big of a company is ADMA Biologics?

ADMA Biologics has a market capitalization of $195.60 million and generates $22.76 million in revenue each year. The biotechnology company earns $-43,750,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. ADMA Biologics employs 295 workers across the globe.

What is ADMA Biologics' official website?

The official website for ADMA Biologics is http://www.admabiologics.com.

How can I contact ADMA Biologics?

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]


MarketBeat Community Rating for ADMA Biologics (NASDAQ ADMA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  260 (Vote Outperform)
Underperform Votes:  156 (Vote Underperform)
Total Votes:  416
MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe ADMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel